230 related articles for article (PubMed ID: 18751744)
1. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
2. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
3. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
Johnson-Jahangir H; Sherman W; Ratner D
J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
[TBL] [Abstract][Full Text] [Related]
4. Current treatment options in dermatofibrosarcoma protuberans.
Lemm D; Mügge LO; Mentzel T; Höffken K
J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
[TBL] [Abstract][Full Text] [Related]
5. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
6. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
[TBL] [Abstract][Full Text] [Related]
7. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
McArthur G
Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
12. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
17. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
[TBL] [Abstract][Full Text] [Related]
18. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
19. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
20. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
Kallini JR; Khachemoune A
J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]